The Establishment of a Registry and a Biorepository of Patients With Suspected Amniotic Fluid Embolism (AFE)

Conditions

• Amniotic Fluid Embolism

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Patient — OTHER
  affected individuals diagnosed with AFE

Study Details

To establish a clinical registry of suspected cases of AFE. The existing registry will be migrated to a new platform,

Key Dates

Start date

Jul 5, 2022

Status verified

May 2026

Primary completion

Oct 1, 2031

Completion

Dec 31, 2031

Study Design

Enrollment

400 participants (estimated)

Arms

• Arm: AFE
  participants of the AFE registry and biorepository include affected individuals diagnosed with AFE All subjects or their next of kin must be able to provide a signed and dated informed consent form. In the case of lethal AFE, the surviving family member or next of kin must be able to provide a signed and dated informed consent form with an accompanying death certificate and proof of legal kinship

Primary Outcome Measure

To establish a clinical registry of suspected cases of AFE [ Time Frame: 1 year ]

Central Contacts

• Miranda Klassen
  760-444-5505
  [email protected]
• Irene Stafford, MD
  713-500-6412
  [email protected]

Locations (1)

Find similar trials in Houston, TX